NVO vs. TEVA: Novo Nordisk vs. Teva Pharmaceutical Stock Comparison
How do Novo Nordisk (NVO) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Novo Nordisk (NVO) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Both Novo Nordisk (NVO) and Teva Pharmaceutical (TEVA) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.
| Profile Item | NVO | TEVA |
|---|---|---|
| Name | Novo Nordisk A/S Sponsored ADR | Teva Pharmaceutical Industries Ltd. ADR |
| Country/Region | Denmark | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 177.74 billion USD | 49.72 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | April 30, 1981 | February 16, 1982 |
| Security Type | ADR | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NVO | TEVA |
|---|---|---|
| Total Return (1Y) | -5.29% | 79.58% |
| Total Return (3Y, Annualized) | -23.41% | 69.94% |
| Total Return (5Y, Annualized) | -4.13% | 35.86% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NVO | TEVA |
|---|---|---|
| Volatility (1Y, Annualized) | 45.98% | 33.95% |
| Beta (5Y) | 0.67 | 0.96 |
| Max Drawdown (5Y) | -74.70% | -43.70% |
| Avg. Volume (3M) | 12.11M | 5.91M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NVO | TEVA |
|---|---|---|
| Sharpe Ratio (1Y) | -0.21 | 2.22 |
| Sortino Ratio (1Y) | -0.28 | 3.94 |
Profitability
ROE (TTM)
Both Novo Nordisk (NVO) at 58.38% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
58.38%
- Max
- 109.18%
- NVO
- 58.38%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Novo Nordisk (NVO) at 33.92% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.92%
- NVO
- 33.92%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Novo Nordisk (NVO) at 40.05% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.05%
- Max
- 83.12%
- NVO
- 40.05%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NVO | TEVA |
|---|---|---|
| ROE (TTM) | 58.38% | 6.65% |
| ROA (TTM) | 19.05% | 5.35% |
| Net Margin (TTM) | 33.92% | 2.94% |
| Operating Margin (TTM) | 40.05% | 27.40% |
| Gross Margin (TTM) | 83.33% | 53.51% |
Growth
Revenue Growth
Both Novo Nordisk (NVO) at 6.43% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Novo Nordisk (NVO) reports EPS growth of 1.77%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.
Growth Metrics
| Metric | NVO | TEVA |
|---|---|---|
| Revenue Growth (YoY) | 6.43% | 4.31% |
| Revenue Growth (3Y CAGR) | 20.43% | 4.96% |
| EPS Growth (YoY) | 1.77% | -- |
| EPS Growth (3Y CAGR) | 23.52% | -- |
Financial Strength
Current Ratio (MRQ)
Both Novo Nordisk (NVO) at 0.85 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.85
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NVO
- 0.85
- Min
- 0.10
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
Debt / Equity (MRQ)
Novo Nordisk (NVO) at 0.62 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.62
- Max
- 1.42
- Q3
- 0.65
- NVO
- 0.62
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NVO | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 0.85 | 0.95 |
| Debt / Equity (MRQ) | 0.62 | 2.13 |
| Net Debt / EBITDA | 0.49 | 2.93 |
Dividends
Dividend Yield (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.03%
- NVO
- 29.03%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.36%
- NVO
- 45.36%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NVO | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 29.03% | 0.00% |
| Dividend Payout Ratio (TTM) | 45.36% | 0.00% |
Valuation
P/E Ratio (TTM)
Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Teva Pharmaceutical (TEVA) at 99.09 trades above its peer range — a wide earnings-valuation gap relative to industry peers.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.18
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- NVO
- 10.18
- Min
- 0.07
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both Novo Nordisk (NVO) at 0.53 and Teva Pharmaceutical (TEVA) at 2.89 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.53
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- NVO
- 0.53
- Min
- 0.01
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Novo Nordisk (NVO) at 5.43 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.43
- Max
- 13.53
- Q3
- 6.54
- NVO
- 5.43
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | NVO | TEVA |
|---|---|---|
| P/E Ratio (TTM) | 10.18 | 99.09 |
| P/S Ratio (TTM) | 0.53 | 2.89 |
| P/B Ratio (MRQ) | 5.43 | 6.23 |
| Free Cash Flow Yield (TTM) | 18.43% | 3.00% |